Topic

Articles

Milan Kalawadia, Senior Vice President, Head of US Commercial Operations at Dr. Reddy‘s, talks about his 15+ years with the India-headquartered company, maintaining a leading position in the generics industry, and the challenges of doing business during the pandemic.

Keeping Cost-Competitive: Milan Kalawadia, Dr. Reddy’s

Insights from AmerisourceBergen EVP and Chief Strategy Officer, Leslie Donato.

How an Innovation Mindset Fuels Revenue Expansion for a Top 10 Fortune 500 Company

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

GSK‘s President of US Pharmaceuticals, Maya Martinez-Davis, outlines her organization’s evolving diversity and inclusion commitments. 

D&I at GSK

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.










Broadening the Scope of Small Molecules: Ventus Therapeutics

Influenced by lessons from the playing field, former rugby athlete James Robinson, today president and CEO of Urovant Sciences, discusses the keys to establishing a high-performing team culture in biopharma—and the end-game wins in treatment gain and patient need.

Coach First, CEO Second

Newly appointed General Manager (UK) at Global Blood Therapeutics (GBT), Nigel Nicholls talks about the company’s vision for Europe and the UK and the health inequity faced by the sickle cell disease community.

Serving Sickle Cell Disease Patients in Europe: Nigel Nicholls, GBT

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

What Does the Future of Work Look Like for America’s Biopharma Sales Force?

Alnylam's new Chief Commercial Officer, Tolga Tanguler, talks about his new role and what he envisions for the company in the next five years.

Advancing Alnylam’s Five-Year Plan: Tolga Tanguler

Building on a lifelong passion for biomedical research, and then its application in policy and health equity as a leader in various interconnected settings, Michelle McMurry-Heath, president and CEO of BIO, is uniquely positioned as a “translator” for science and social advocacy—and speaking stakeholders to action.

A Steward of Science

Amgen board member and serial CEO Fred Hassan talks about the three levers  Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Executive Profiles